Skip to content

EV / EBITDA at other companies

UnitedHealth Group logo
UnitedHealth GroupUNH
12.8×-1.3×
Encompass Health Corporation logo
Encompass Health CorporationEHC
8.6×-2.0×
HCA Healthcare logo
HCA HealthcareHCA
9.9×+0.6×
Astrana Health logo
Astrana HealthASTH
13.8×-0.8×
Universal Health Services logo
Universal Health ServicesUHS
-1.4×
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
19×+3.3×

Other financials

Income statement

See full
Revenue$810.9M+4.5%
Operating income$65.8M+6.3%
Net income-$35.9M+4.8%
EPS (diluted)-$0.28+6.7%

Balance sheet

See full
Cash & equivalents$182.3M-20.5%
Total debt$5.1B+4.6%
Total equity$1.7B-3.0%
Total assets$8.0B+1.2%

Cash flow

See full
Operating cash flow$11.7M+95.0%
CapEx$16.0M-29.5%
Free cash flow-$4.3M+74.3%

Valuation

See full
Market cap$1.9B-49.1%
Enterprise value$6.77B-16.0%
P/S0.6×-0.6×

Profitability

See full
Gross margin23.1%
Operating margin11.8%+1.2pp
Net margin-2.3%-0.9pp
FCF margin6.2%+0.8pp

Returns & leverage

See full
Return on equity-4.4%-1.6pp
Debt / equity+0.2×
Current ratio1.9×0.0×

Where this comes from

Calculated from Surgery Partners, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Surgery Partners, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Surgery Partners, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Surgery Partners, Inc.'s EV / EBITDA?
Surgery Partners, Inc. (SGRY) reported EV / EBITDA of 11.2× in Q1 2026.
How has Surgery Partners, Inc.'s EV / EBITDA changed year-over-year?
Surgery Partners, Inc.'s EV / EBITDA decreased by 28.0% year-over-year, from 15.6× to 11.2×.
What is the long-term trend for Surgery Partners, Inc.'s EV / EBITDA?
Over 5 years (2020 to 2025), Surgery Partners, Inc.'s EV / EBITDA has grown at a -10.4% compound annual growth rate (CAGR), from 20.9× to 12.1×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.